Mutual of America Capital Management LLC Buys 3,978 Shares of Bruker Co. (NASDAQ:BRKR)

Mutual of America Capital Management LLC grew its stake in shares of Bruker Co. (NASDAQ:BRKR) by 7.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 59,728 shares of the medical research company’s stock after buying an additional 3,978 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Bruker were worth $4,125,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Horizon Advisors Inc. grew its stake in shares of Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after buying an additional 218 shares during the last quarter. Covestor Ltd grew its stake in shares of Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after purchasing an additional 210 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Bruker in the second quarter worth $52,000. Finally, GAMMA Investing LLC grew its stake in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after purchasing an additional 388 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Barclays reduced their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. TD Cowen reduced their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Citigroup reduced their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and an average target price of $79.36.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 28.30% of the company’s stock.

Bruker Trading Up 5.2 %

NASDAQ:BRKR opened at $56.17 on Friday. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $8.52 billion, a price-to-earnings ratio of 27.00, a PEG ratio of 2.31 and a beta of 1.20. The firm has a fifty day simple moving average of $61.63 and a two-hundred day simple moving average of $64.77. Bruker Co. has a 12 month low of $48.07 and a 12 month high of $94.86.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 earnings per share. Analysts expect that Bruker Co. will post 2.4 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date is Monday, December 2nd. Bruker’s payout ratio is 9.62%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.